IBUPROFEN Drug Interactions
Also known as: good neighbor pharmacy ibuprofen
IBUPROFEN (brand name: good neighbor pharmacy ibuprofen) is a NSAIDs. Uses • temporarily relieves minor aches and pains due to: • headache • muscular aches • minor pain of arthritis • toothache • backache • the common cold • menstrual cramps • temporarily reduces feverIBUPROFEN has 24 documented drug interactions in our database, including 0 contraindicated, 17 major, 6 moderate, and 1 minor interactions.
0
Contraindicated
17
Major
6
Moderate
1
Minor
Combining ibuprofen with aspirin 81 mg can significantly increase your risk of bleeding, especially in the stomach or intestines. It's important to discuss this with your doctor before taking both medications.
Mechanism
Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, leading to reduced prostaglandin synthesis and impaired platelet aggregation. Aspirin 81 mg also inhibits platelet aggregation, primarily through irreversible inhibition of COX-1. The concurrent use of these agents results in an additive antiplatelet effect and increased gastrointestinal mucosal damage, synergistically elevating bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, which can range from mild symptoms to life-threatening hemorrhage. This combination can lead to peptic ulcers, melena, hematemesis, or even hemorrhagic stroke. The risk of serious GI bleeding is significantly elevated, potentially 3-5 times higher than with either drug alone. Concurrent use of ibuprofen and aspirin 81 mg should generally be avoided due to the high bleeding risk. If pain relief is needed while on aspirin, acetaminophen is a safer alternative. If NSAID use is unavoidable, consider a COX-2 selective NSAID or a proton pump inhibitor (PPI) for gastroprotection, and monitor closely for signs of bleeding. Patients should be educated to report any signs of bleeding immediately.
Combining ibuprofen with apixaban significantly increases your risk of bleeding, especially from the stomach or intestines. This combination should generally be avoided.
Mechanism
Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), inhibits platelet aggregation and can cause direct irritation and damage to the gastrointestinal lining. Apixaban is a direct oral anticoagulant (DOAC) that prevents blood clotting by inhibiting Factor Xa. Their combined use results in an additive antiplatelet and anticoagulant effect, disrupting normal hemostasis.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other serious bleeding events. The risk of major gastrointestinal bleeding can be 3 to 15 times higher when NSAIDs are combined with anticoagulants compared to anticoagulants alone. This combination should generally be avoided due to the high bleeding risk. If pain management is necessary, consider alternative analgesics such as acetaminophen. If an NSAID is absolutely required, use the lowest effective dose for the shortest duration, and monitor closely for signs of bleeding (e.g., black/tarry stools, unusual bruising, blood in urine). Proton pump inhibitor co-therapy may be considered to reduce GI bleeding risk.
Combining ibuprofen with rivaroxaban significantly increases your risk of serious bleeding, including bleeding in the stomach or intestines. This combination should generally be avoided.
Mechanism
Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, leading to decreased prostaglandin synthesis and impaired platelet aggregation. Rivaroxaban is a direct oral anticoagulant (DOAC) that directly inhibits Factor Xa, preventing thrombin generation and clot formation. The concurrent use of these agents results in additive antiplatelet and anticoagulant effects, markedly increasing the risk of bleeding.
Clinical Management
The primary clinical effect is a substantially elevated risk of bleeding. This can manifest as gastrointestinal bleeding (e.g., stomach ulcers, melena, hematemesis), bruising, nosebleeds, or more severe internal bleeding. Studies show that combining NSAIDs with DOACs can increase the risk of major bleeding by 2 to 3 times compared to DOAC monotherapy. This combination should be avoided if possible. If pain relief is necessary, consider alternative analgesics such as acetaminophen. If an NSAID is absolutely required, use the lowest effective dose for the shortest duration, and monitor closely for signs of bleeding. Proton pump inhibitors (PPIs) may be considered for gastroprotection, but do not eliminate the risk. Evaluate the patient's overall bleeding risk factors.
Taking ibuprofen with argatroban significantly increases your risk of bleeding, including serious internal bleeding. You should avoid this combination unless specifically directed by your doctor.
Mechanism
Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and impairing platelet aggregation. Argatroban is a direct thrombin inhibitor, which prevents clot formation. The combined antiplatelet effect of ibuprofen and the anticoagulant effect of argatroban lead to a synergistic increase in bleeding risk.
Clinical Management
The primary clinical effect is a significantly increased risk of bleeding, including gastrointestinal bleeding, intracranial hemorrhage, and other serious hemorrhagic events. Patients may experience symptoms such as bruising, nosebleeds, blood in urine or stool, or severe abdominal pain. The risk of major bleeding is substantially elevated compared to using either drug alone. This combination should generally be avoided due to the high risk of bleeding. If an analgesic is required, acetaminophen is a safer alternative. If NSAID use is absolutely essential, close monitoring for signs of bleeding is critical, and the lowest effective dose for the shortest duration should be used. Consider alternative anticoagulant strategies if possible.
Combining ibuprofen with bivalirudin significantly increases your risk of bleeding, including serious internal bleeding. Your doctor may need to adjust your medications or monitor you closely.
Mechanism
Ibuprofen, an NSAID, inhibits platelet aggregation and can cause gastrointestinal irritation and ulceration. Bivalirudin, a direct thrombin inhibitor, prevents clot formation. The combined effect of impaired platelet function and reduced coagulation, along with potential GI mucosal damage from ibuprofen, leads to a heightened risk of hemorrhage.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, which can range from minor bruising or nosebleeds to severe, life-threatening gastrointestinal hemorrhage, intracranial bleeding, or other major bleeding events. Studies suggest that combining NSAIDs with anticoagulants can increase the risk of GI bleeding by 3 to 15 times. This combination should generally be avoided due to the high bleeding risk. If concurrent use is unavoidable, patients require very close monitoring for signs of bleeding (e.g., black/tarry stools, unusual bruising, blood in urine, severe headache). Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen. If an NSAID is absolutely necessary, use the lowest effective dose for the shortest duration possible, and consider a proton pump inhibitor for GI protection.
Concomitant use of warfarin and ibuprofen significantly increases the risk of bleeding, including serious gastrointestinal bleeding. Patients may experience bruising, nosebleeds, or more severe hemorrhagic events requiring medical intervention.
Mechanism
Warfarin inhibits vitamin K-dependent clotting factors, leading to anticoagulation. Ibuprofen, an NSAID, inhibits platelet aggregation and can cause gastric irritation, both of which contribute to an increased risk of bleeding when combined with warfarin.
Clinical Management
Avoid concurrent use if possible. If co-administration is necessary, closely monitor patients for signs of bleeding, particularly gastrointestinal bleeding, and frequently check INR levels. Consider alternative analgesics like acetaminophen.
Taking ibuprofen with warfarin significantly increases your risk of serious bleeding, especially from the stomach or intestines. It is generally advised to avoid this combination due to the heightened danger.
Mechanism
Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), inhibits platelet aggregation and can cause direct irritation and damage to the gastrointestinal lining. Warfarin, an anticoagulant, reduces the production of clotting factors. The combined effect leads to a synergistic increase in bleeding risk.
Clinical Management
This interaction can lead to severe bleeding complications, including gastrointestinal hemorrhage, intracranial hemorrhage, and other internal bleeding, which can be life-threatening. The risk of major gastrointestinal bleeding is estimated to be 3-15 times higher when NSAIDs are co-administered with warfarin. This combination should generally be avoided. If pain relief is necessary, consider acetaminophen as a safer alternative. If NSAID use is unavoidable, use the lowest effective dose for the shortest duration, and monitor INR more frequently for potential elevation. Patients should be educated on signs of bleeding and seek immediate medical attention if they occur.
Combining ibuprofen with dabigatran significantly increases your risk of serious bleeding, especially from the stomach or intestines. This combination should generally be avoided.
Mechanism
Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, leading to reduced prostaglandin synthesis and impaired platelet aggregation. Dabigatran is a direct thrombin inhibitor that prevents the formation of blood clots. The concurrent use of these agents results in an additive antiplatelet and anticoagulant effect, significantly increasing the risk of bleeding.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, which can be severe or even life-threatening. Studies show that co-administration of NSAIDs with DOACs can increase the risk of major bleeding events by 2 to 3-fold compared to DOACs alone. This combination should be avoided if possible. If pain relief is necessary, consider alternative analgesics such as acetaminophen. If an NSAID is deemed essential, use the lowest effective dose for the shortest duration, and monitor closely for signs of bleeding (e.g., black/tarry stools, unusual bruising). Consider gastroprotective agents (e.g., proton pump inhibitors) if NSAID use is unavoidable.
Combining ibuprofen with edoxaban significantly increases your risk of bleeding, especially in the stomach and intestines. This combination should generally be avoided.
Mechanism
Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which reduces the protective mucosal barrier in the gastrointestinal tract and impairs platelet function. Edoxaban is a direct oral anticoagulant that inhibits Factor Xa, preventing clot formation. The concurrent use of both agents leads to additive antiplatelet and anticoagulant effects, alongside increased gastrointestinal mucosal damage.
Clinical Management
The primary clinical effect is a substantially increased risk of serious bleeding, particularly gastrointestinal bleeding (e.g., stomach ulcers, melena, hematemesis). The risk of major bleeding can be several-fold higher compared to using either drug alone. Other bleeding events, such as epistaxis, hematuria, or bruising, may also be exacerbated. This combination should generally be avoided due to the high risk of bleeding. If an NSAID is absolutely necessary, consider alternative pain management strategies or a short course of a COX-2 selective NSAID (e.g., celecoxib), though this still carries significant risk. Close monitoring for signs of bleeding is crucial, and patients should be educated on symptoms requiring immediate medical attention. Proton pump inhibitors may be considered for gastroprotection if short-term use is unavoidable.
Combining ibuprofen with heparin significantly increases your risk of bleeding, including serious internal bleeding. This combination should generally be avoided.
Mechanism
Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), inhibits platelet aggregation and can cause gastrointestinal mucosal damage. Heparin is an anticoagulant that directly inhibits clotting factors, thereby prolonging clotting time. The combined antiplatelet and anticoagulant effects are additive, leading to a synergistic increase in bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, which can manifest as gastrointestinal bleeding (e.g., ulcers, melena), bruising, epistaxis, hematuria, or more severe internal hemorrhages (e.g., intracranial, retroperitoneal). Studies show a 3-15 fold increased risk of GI bleeding when NSAIDs are co-administered with anticoagulants. This combination should generally be avoided due to the high bleeding risk. If concurrent use is unavoidable, close monitoring for signs of bleeding is essential, and the lowest effective doses for the shortest duration should be used. Consider alternative pain management strategies or alternative anticoagulants if clinically appropriate. Proton pump inhibitors may be co-prescribed to reduce GI bleeding risk.
Combining ibuprofen with enoxaparin significantly increases your risk of bleeding, especially in the stomach or intestines. This combination should generally be avoided due to the heightened risk of serious complications.
Mechanism
Ibuprofen, an NSAID, inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and impairing platelet aggregation. Enoxaparin, a low molecular weight heparin, directly inhibits Factor Xa, preventing clot formation. The concurrent use of these agents leads to additive antiplatelet and anticoagulant effects, severely compromising hemostasis.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other serious bleeding events. Studies suggest the risk of major bleeding can be several-fold higher compared to either drug alone. This combination should generally be avoided. If an NSAID is absolutely necessary, consider alternative pain management strategies or a COX-2 selective NSAID with extreme caution, and only under strict medical supervision. Monitor closely for signs of bleeding (e.g., black/tarry stools, unusual bruising, nosebleeds) and hemoglobin levels. Proton pump inhibitors may be co-prescribed to reduce GI bleeding risk if NSAID use is unavoidable.
Combining ibuprofen with fondaparinux significantly increases your risk of serious bleeding, especially in the stomach or intestines. Your doctor may need to adjust your medications or choose safer alternatives.
Mechanism
Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair platelet function and damage the gastrointestinal mucosa. Fondaparinux is a selective factor Xa inhibitor, directly reducing thrombin generation. The concurrent use leads to additive antiplatelet and anticoagulant effects, severely impairing the body's ability to form clots.
Clinical Management
This combination substantially elevates the risk of major bleeding events, including gastrointestinal hemorrhage, intracranial bleeding, and hematoma formation. The risk of GI bleeding can be 3-15 times higher than with either drug alone, and overall major bleeding risk is significantly increased. Avoid concurrent use of ibuprofen and fondaparinux whenever possible. If an NSAID is absolutely necessary, consider a COX-2 selective inhibitor (e.g., celecoxib) with caution and close monitoring, or a non-NSAID analgesic. Monitor closely for signs of bleeding (e.g., black/tarry stools, unusual bruising, nosebleeds) and hemoglobin levels. Proton pump inhibitors may be co-prescribed to reduce GI bleeding risk if NSAID use is unavoidable.
Combining ibuprofen with dipyridamole significantly increases your risk of bleeding, especially from the stomach or intestines. This combination should generally be avoided.
Mechanism
Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and impairing platelet aggregation. Dipyridamole is an antiplatelet agent that inhibits phosphodiesterase, leading to increased cyclic AMP and further impairing platelet function. The concomitant use results in additive antiplatelet effects and increased gastrointestinal mucosal damage.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, including gastrointestinal bleeding (e.g., ulcers, melena, hematemesis), intracranial hemorrhage, and other forms of hemorrhage. The risk of serious gastrointestinal bleeding with NSAID plus antiplatelet therapy can be several-fold higher compared to either agent alone. This combination should generally be avoided due to the high bleeding risk. If concurrent use is unavoidable, the patient should be closely monitored for signs of bleeding (e.g., black/tarry stools, unusual bruising, weakness) and the lowest effective doses for the shortest duration should be used. Consider alternative pain management strategies or antiplatelet agents if appropriate. Gastroprotective agents (e.g., proton pump inhibitors) may be considered but do not eliminate the risk.
Combining ibuprofen with ticagrelor significantly increases your risk of bleeding, especially from the stomach or intestines. This combination should generally be avoided due to the heightened bleeding potential.
Mechanism
Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and impairing platelet aggregation. Ticagrelor is an antiplatelet agent that directly inhibits the P2Y12 receptor, preventing ADP-mediated platelet activation and aggregation. The concurrent use of these agents leads to additive antiplatelet effects and increased gastrointestinal mucosal damage, profoundly elevating bleeding risk.
Clinical Management
Patients taking both ibuprofen and ticagrelor are at a substantially increased risk of serious bleeding events, including gastrointestinal hemorrhage, intracranial hemorrhage, and other major bleeding. The risk of gastrointestinal bleeding can be several-fold higher compared to ticagrelor alone, potentially leading to anemia, hospitalization, or even death. This combination should generally be avoided. If pain management is necessary, consider alternative analgesics such as acetaminophen. If an NSAID is absolutely required, use the lowest effective dose for the shortest possible duration, and consider gastroprotective agents (e.g., proton pump inhibitors). Closely monitor for signs of bleeding (e.g., black/tarry stools, unusual bruising, blood in urine).
Combining ibuprofen with clopidogrel significantly increases your risk of bleeding, especially in the stomach or intestines. Your doctor may need to adjust your medications or monitor you closely.
Mechanism
Ibuprofen, an NSAID, inhibits cyclooxygenase (COX) enzymes, leading to reduced prostaglandin synthesis and impaired platelet aggregation. Clopidogrel is an antiplatelet agent that irreversibly blocks the P2Y12 ADP receptor on platelets, preventing platelet activation and aggregation. The concurrent use of both drugs results in additive antiplatelet effects, profoundly increasing the risk of bleeding.
Clinical Management
Patients taking both ibuprofen and clopidogrel face a substantially elevated risk of serious bleeding events, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other systemic bleeding. The risk of major GI bleeding can be several-fold higher compared to either drug alone. Symptoms may include black or tarry stools, blood in vomit, prolonged bleeding from cuts, or unexplained bruising. Concurrent use should generally be avoided due to the high bleeding risk. If an NSAID is absolutely necessary, consider alternatives with lower GI risk like celecoxib, or topical NSAIDs, for the shortest duration possible. Close monitoring for signs of bleeding is crucial, and proton pump inhibitor (PPI) co-administration should be considered to reduce GI bleeding risk. Re-evaluate the necessity of both agents and consider alternative pain management strategies.
Taking ibuprofen with prasugrel significantly increases your risk of serious bleeding, especially in the stomach or intestines. You should avoid this combination unless specifically directed by your doctor.
Mechanism
Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, which reduces prostaglandin synthesis and impairs platelet aggregation. Prasugrel is an antiplatelet medication that irreversibly blocks the P2Y12 ADP receptor on platelets, preventing their activation and aggregation. The combined antiplatelet effects of both drugs lead to a synergistic increase in bleeding risk.
Clinical Management
The primary clinical effect is a significantly increased risk of bleeding, including gastrointestinal (GI) bleeding, intracranial hemorrhage, and other serious bleeding events. The risk of GI bleeding can be several-fold higher compared to either drug alone, potentially leading to anemia, hospitalization, or even death. This combination should generally be avoided due to the high risk of serious bleeding. If pain relief is needed, consider alternative analgesics such as acetaminophen. If an NSAID is deemed absolutely necessary, use the lowest effective dose for the shortest duration, and monitor closely for signs of bleeding. Proton pump inhibitors (PPIs) may be co-prescribed to reduce GI bleeding risk, but do not eliminate it.
Combining ibuprofen with cilostazol significantly increases your risk of bleeding, especially in the stomach or intestines. This combination should generally be avoided.
Mechanism
Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, leading to reduced prostaglandin synthesis and impaired platelet aggregation. Cilostazol is a phosphodiesterase-3 inhibitor that directly inhibits platelet aggregation and causes vasodilation. The additive antiplatelet effects of both drugs lead to a synergistic increase in bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, which can manifest as stomach pain, black or tarry stools, or vomiting blood. Other bleeding events like bruising, nosebleeds, or prolonged bleeding from cuts are also more likely. The risk of serious GI bleeding can be significantly elevated, potentially several-fold higher than with either drug alone. This combination should generally be avoided due to the high risk of bleeding. If concurrent use is unavoidable, patients must be closely monitored for signs of bleeding, and the lowest effective doses for the shortest duration should be used. Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen. Proton pump inhibitors may be considered for gastroprotection if NSAID use is essential, but this does not mitigate the antiplatelet interaction.
Concomitant use of lisinopril and ibuprofen can increase the risk of acute kidney injury, particularly in elderly or volume-depleted patients. It may also reduce the antihypertensive effects of lisinopril, leading to uncontrolled blood pressure.
Mechanism
Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis. Prostaglandins are crucial for maintaining renal blood flow, especially when the renin-angiotensin-aldosterone system (RAAS) is inhibited by lisinopril. This can lead to impaired renal function and fluid retention.
Clinical Management
Avoid concomitant use if possible, especially in patients at high risk for renal impairment (e.g., elderly, dehydrated, heart failure). If co-administration is necessary, monitor renal function (serum creatinine, BUN) and blood pressure closely, particularly at initiation and dose changes. Advise patients to maintain adequate hydration.
Concurrent use of ibuprofen with atenolol may reduce the antihypertensive effects of atenolol, potentially leading to elevated blood pressure. This interaction is more pronounced with chronic NSAID use and in patients with pre-existing hypertension or heart failure.
Mechanism
Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis. Prostaglandins play a role in maintaining renal blood flow and sodium excretion, and their inhibition can lead to sodium and fluid retention, which counteracts the blood pressure-lowering effects of atenolol.
Clinical Management
Monitor blood pressure closely when initiating or discontinuing ibuprofen in patients taking atenolol. If blood pressure control is compromised, consider alternative analgesics or increasing the dose of atenolol, if appropriate. Advise patients to use the lowest effective dose of ibuprofen for the shortest duration necessary.
Concomitant use of ibuprofen and losartan can lead to a decrease in the antihypertensive effect of losartan and an increased risk of renal dysfunction, particularly in elderly, dehydrated, or renally impaired patients. This combination can also increase the risk of hyperkalemia.
Mechanism
Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can counteract the vasodilator effects of losartan and lead to sodium and water retention. In susceptible patients, this can impair renal perfusion and function when combined with the angiotensin receptor blockade of losartan.
Clinical Management
Monitor blood pressure closely when initiating or discontinuing ibuprofen in patients on losartan. Assess renal function (e.g., serum creatinine, GFR) and serum potassium levels regularly, especially in high-risk patients. Advise patients to maintain adequate hydration.
Concomitant use of ibuprofen and naproxen, both non-steroidal anti-inflammatory drugs (NSAIDs), is generally not recommended due to an increased risk of gastrointestinal (GI) adverse effects, including ulcers, bleeding, and perforation, as well as renal toxicity. While they may offer additive analgesic effects, the increased risk of side effects typically outweighs the benefits.
Mechanism
Both ibuprofen and naproxen exert their therapeutic and adverse effects primarily through the non-selective inhibition of cyclooxygenase (COX) enzymes, COX-1 and COX-2. Concurrent administration leads to an additive pharmacological effect, resulting in a higher degree of prostaglandin inhibition and, consequently, an increased risk of dose-dependent adverse events.
Clinical Management
Avoid co-administration of ibuprofen and naproxen. If an NSAID is required, use a single agent at the lowest effective dose for the shortest duration necessary. If pain relief is inadequate with one NSAID, consider switching to an alternative analgesic class or adding a different modality rather than combining NSAIDs.
Ibuprofen can interfere with the antiplatelet effect of low-dose aspirin, which is used for cardiovascular prophylaxis. This interaction may reduce aspirin's ability to prevent blood clots, potentially increasing the risk of cardiovascular events.
Mechanism
Ibuprofen, by reversibly binding to the cyclooxygenase-1 (COX-1) enzyme, can block aspirin's irreversible binding site. If ibuprofen is taken before aspirin, it prevents aspirin from acetylating COX-1 in platelets, thereby diminishing aspirin's antiplatelet effect.
Clinical Management
To minimize this interaction, patients taking low-dose aspirin for cardiovascular protection should take ibuprofen at least 30 minutes after or 8 hours before their daily aspirin dose. If frequent ibuprofen use is necessary, alternative analgesics like acetaminophen or other NSAIDs that do not interfere with aspirin's antiplatelet effect (e.g., celecoxib) should be considered.
Concomitant use of meloxicam and ibuprofen, both nonsteroidal anti-inflammatory drugs (NSAIDs), significantly increases the risk of serious gastrointestinal adverse events, including ulcers, bleeding, and perforation. It also elevates the risk of acute kidney injury and cardiovascular thrombotic events without providing additional analgesic benefit.
Mechanism
Both meloxicam and ibuprofen inhibit prostaglandin synthesis through cyclooxygenase (COX) enzymes. Their combined use leads to an additive pharmacodynamic effect, resulting in greater suppression of protective prostaglandins in the gastrointestinal tract and kidneys.
Clinical Management
Avoid concomitant use of meloxicam and ibuprofen. If an NSAID is required, use a single agent at the lowest effective dose for the shortest duration possible. Consider alternative analgesic strategies or gastroprotective agents if NSAID therapy is unavoidable and the patient is at high risk.
NSAIDs may slightly reduce metformin's renal clearance and increase the risk of lactic acidosis in patients with renal impairment.
Mechanism
NSAIDs reduce renal blood flow and GFR, potentially reducing metformin elimination and increasing plasma levels.
Clinical Management
Use with caution in patients with renal impairment. Monitor renal function. Use acetaminophen as an alternative when possible.
For complete prescribing information:
View full IBUPROFEN monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.